

Date: July 27, 2023

BSE Limited

P.J. Towers, Dalal Street, Fort,

Mumbai 400 001

BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra (East),

Mumbai – 400 051

NSE symbol: PPLPHARMA

Sub: Outcome of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited (“Company”) held on July 27, 2023 - Intimation pursuant to Regulation 30 and 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is further to our intimation on the outcome of the meeting of the board of directors of the Company (“**Board**”) dated February 8, 2023, where the issue of fully paid-up equity shares of the Company of face value of ₹10 each (“**Equity Shares**”) was approved by way of a rights issue for an amount not exceeding ₹1,050 crore (“**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rule made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws.

Pursuant to the above referred, the Committee of Directors (Rights Issue) at its meeting held today, July 27, 2023, has *inter alia* considered and approved the following terms of the Rights Issue:

- a. **Instrument:** Fully paid-up Equity Shares of face value of ₹10 each;
- b. **Total number of Equity Shares and Rights Issue size:** 129,629,630 fully paid-up Equity Shares each for amount aggregating up to ₹1,050 crore;
- c. **Rights Issue Price:** ₹81.00 per fully paid-up Equity Share [including a premium of ₹ 71 per Equity Share];
- d. **Record Date:** Wednesday, August 2, 2023 designated for the purpose of determining the existing equity shareholders entitled to receive the rights entitlement in the Rights Issue (“**Eligible Equity Shareholders**”)
- e. **Rights Issue period:**
 1. Rights Issue Opening Date: Tuesday day, August 8, 2023
 2. Rights Issue Closing Date: Wednesday day, August 16, 2023
- f. **Outstanding Equity Shares:**
 1. prior to the Rights Issue: 1,19,33,18,500 fully paid Equity Shares;
 2. post Rights Issue[#]: 1,322,948,130 fully paid Equity Shares.
#assuming full subscription
- g. **Rights Entitlement Ratio:** 5:46 (Number of Rights Equity Shares that an Eligible Equity Shareholder is entitled to in proportion to the number of Equity Shares held by such Eligible Equity Shareholder on the Record Date, in this case being 5 Rights Equity Shares for every 46 Equity Shares held by an Eligible Equity Shareholder.)
- h. **Other terms of the Rights Issue (including fractional and zero entitlements):** To be included in the Letter of Offer to be filed by the Company with Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited.

Piramal Pharma Limited

CIN : U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com

Further, in terms of SEBI master circular bearing number SEBI/HO/CFD/PoD- 2/P/CIR/2023/00094 dated June 21, 2023, as amended, the Company has made necessary arrangement with NSDL and CDSL for the credits of the rights entitlements in dematerialized form in the demat account of the Eligible Equity Shareholders as on the Record Date. The ISIN of such rights entitlement is INE0DK520011. The rights entitlement of the Eligible Equity Shareholders as on the Record Date, shall be credited prior to the issue opening date, in the respective demat account of the eligible equity shareholders under the aforementioned ISIN.

Additionally, the Board also approved the Letter of Offer to be submitted with Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited.

This intimation is issued in terms of Regulation 30 and 42 of the SEBI Listing Regulations.

You are requested to kindly take note of the same.

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN : U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com